ABCL
NASDAQ HealthcareAbCellera Biologics Inc. - Common Shares
Biotechnology
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
�� 市场数据
| 价格 | $6.13 |
|---|---|
| 成交量 | 7,736,877 |
| 市值 | 1.87B |
| RSI（14日） | 65.6 |
| 200日均线 | $4.19 |
| 50日均线 | $4.28 |
| 52周最高 | $6.79 |
| 52周最低 | $2.09 |
| Forward P/E | -8.51 |
| Price / Book | 1.99 |
🎯 投资策略评分
ABCL 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (77/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ABCL in your text
粘贴任何文章、记录或帖子 — 工具将提取 ABCL 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.